Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fennec Pharmaceuticals Inc (FRX.TO)

Fennec Pharmaceuticals Inc (FRX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 167,337
  • Shares Outstanding, K 27,432
  • Annual Sales, $ 21,252 K
  • Annual Income, $ -16,045 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.92
  • Price/Sales 2.25
  • Price/Cash Flow 5.12
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $-0.21 on 11/08/24
  • Next Earnings Date 11/07/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.24
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.65 unch
on 11/15/24
6.90 -18.12%
on 11/06/24
-0.72 (-11.30%)
since 10/15/24
3-Month
5.65 unch
on 11/15/24
7.80 -27.56%
on 08/26/24
-1.85 (-24.67%)
since 08/15/24
52-Week
5.65 unch
on 11/15/24
15.43 -63.38%
on 12/28/23
-5.10 (-47.44%)
since 11/10/23

Most Recent Stories

More News
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

FRX.TO : 5.65 (-7.38%)
FENC : 3.99 (-9.32%)
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

FRX.TO : 5.65 (-7.38%)
FENC : 3.99 (-9.32%)
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

FRX.TO : 5.65 (-7.38%)
FENC : 3.99 (-9.32%)
Stocks in play: Fennec Pharmaceuticals Inc.

Announced that it has strengthened its executive leadership team with the appointments of Pierre S. ...

FRX.TO : 5.65 (-7.38%)
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

FRX.TO : 5.65 (-7.38%)
FENC : 3.99 (-9.32%)
Stocks in play: Fennec Pharmaceuticals Inc.

Reported its financial results for the fiscal year ended December 31, 2023. Net losses for the fourth ...

FRX.TO : 5.65 (-7.38%)
Stocks in play: Fennec Pharmaceuticals Inc.

Will release its full-year and fourth-quarter 2023 financial results before the opening of the U.S. ...

FRX.TO : 5.65 (-7.38%)
Stocks in play: Fennec Pharmaceuticals Inc.

Will release its first-quarter 2023 financial results before the opening of the U.S. financial markets ...

FRX.TO : 5.65 (-7.38%)
Stocks in play: Fennec Pharmaceuticals Inc.

Today reported its financial results for the fiscal year ended December 31, 2022. Net losses for the ...

FRX.TO : 5.65 (-7.38%)
Stocks in play: Fennec Pharmaceuticals Inc

Announced that the U.S. Food and Drug Administration has granted Orphan Drug Exclusivity to PEDMARK® ...

FRX.TO : 5.65 (-7.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

See More

Key Turning Points

3rd Resistance Point 6.40
2nd Resistance Point 6.25
1st Resistance Point 5.95
Last Price 5.65
1st Support Level 5.50
2nd Support Level 5.35
3rd Support Level 5.05

See More

52-Week High 15.43
Fibonacci 61.8% 11.69
Fibonacci 50% 10.54
Fibonacci 38.2% 9.39
Last Price 5.65
52-Week Low 5.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar